

NeuroLight, Inc. Successfully Completes Phase I NSF/SBIR Grant, Paving the Way for Innovative Sleep Therapy

NeuroLight, Inc. has successfully completed its Phase I NSF/SBIR grant and submitted Outcomes Report, detailing progress in developing neuro-mod sleep technology.

POMONA, NEW YORK, UNITED STATES, July 1, 2024 /EINPresswire.com/ -- NeuroLight, Inc., a pioneering neuroscience-based company, announced the successful completion of its Phase I National Science Foundation (NSF/SBIR) grant.



The Company has submitted its Outcomes Report, detailing significant progress in developing a novel [neuromodulation](#) device aimed at improving [sleep](#) quality and addressing [insomnia](#).



Our Phase I study has demonstrated the feasibility of NeuroMask™, a new approach to improving sleep. By leveraging the power of neuromodulation, we are opening new avenues for drug-free sleep therapy.”

Alexander Poltorak, President and Founder of NeuroLight

Key Achievements:

1. Extracted and analyzed unique cortical signatures associated with sleep stages and transitions, including discovering previously unknown brainwave patterns associated with stage transitions.
2. Developed alpha prototype of NeuroMask™, an innovative sleep mask that uses light and sound for brain entrainment.
3. Established the technical foundation for a next-generation sleep modulation device.

“Our Phase I study has demonstrated the feasibility of NeuroMask™, a novel approach to improving sleep health,” said Alexander Poltorak, President and Founder of NeuroLight. “By leveraging the power of brain entrainment technology, we are opening new avenues for non-

invasive, drug-free sleep therapy.”

The Company’s innovative approach is supported by several U.S. patents, underlining the unique nature of its technology. NeuroLight’s work has the potential to address a major public health concern, offering hope to millions suffering from chronic sleep issues.

Building on this success, NeuroLight plans to apply for a Phase II NSF/SBIR grant to further advance the development of NeuroMask™. The Company aims to refine the device design, conduct a proof-of-concept sleep study, and pursue FDA clearance as a medical device for treating insomnia.

For more information about NeuroLight and its innovative sleep technology, please visit www.NeuroLight.co.

About NeuroLight, Inc.:
NeuroLight, Inc. is a neuromodulation R&D company developing pioneering technology for transplanting mental states™ from one person to another. The first application the company is working on is the potential treatment of insomnia using photobiomodulation and auditory stimulation of the brain.

The Company’s flagship product, NeuroMask™, aims to revolutionize sleep therapy through non-invasive light and sound stimulation. For more information, visit the company’s website at www.NeuroLight.co. NeuroLight is funded by a grant from the National Science Foundation (NSF/SBIR).

Alexander Poltorak
NeuroLight, Inc.
+1 845-368-2500



Alexander Poltorak



NeuroMask™

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/724215455>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.